Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and ...

Red blood cells have several characteristics that make them a potentially ... Inc. , a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of ...

Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46, in combination with enzalutamide in patients with me ...

SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the third quarter 2024 and provided an update on the company’s recent developments.

B12 plays a role in supporting red blood cell formation, meaning it helps to control energy release, reduce fatigue, and, you ...

A University of Rochester hospital will open a patient study comparing the efficacy of SCD treatments to help families in ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...